株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

特発性肺線維症:パイプライン製品の分析

Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 232804
出版日 ページ情報 英文 254 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.08円で換算しております。
Back to Top
特発性肺線維症:パイプライン製品の分析 Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2017
出版日: 2017年05月16日 ページ情報: 英文 254 Pages
概要

特発性肺線維症(IPF)は、肺の孤立性の進行性疾患です。空咳、息切れ(特に運動中/運動後)、持続的な疲労、体重減少などの症状が見られます。治療は、抗酸化剤、生物学的反応修飾物質、抗線維化剤、抗凝固剤などが含まれます。

当レポートでは、特発性肺線維症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

I特発性肺線維症 - 概要

I特発性肺線維症 - 治療薬の開発

  • パイプラインの概要
  • 企業別のパイプライン動向
  • 大学・研究機関別のパイプライン動向
  • 企業で開発中の製品
  • 大学・研究機関で開発中の製品

I特発性肺線維症 - 治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

I特発性肺線維症の治療薬開発に従事している企業

  • AdAlta Ltd
  • Aeolus Pharmaceuticals Inc
  • Allinky Biopharma
  • apceth Biopharma GmbH
  • Apellis Pharmaceuticals Inc
  • 旭化成ファーマ
  • aTyr Pharma Inc
  • Biogen Inc
  • Bioneer Corp
  • BLR Bio LLC
  • Bristol-Myers Squibb Company
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Chiesi Farmaceutici SpA
  • Compugen Ltd
  • Cynata Therapeutics Ltd
  • F. Hoffmann-La Roche Ltd
  • FibroGen Inc
  • FibroStatin SL
  • Galapagos NV
  • GenKyoTex SA
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • Global Blood Therapeutics Inc
  • GNI Group Ltd
  • Histocell SL
  • iBio Inc
  • Inventiva
  • Isarna Therapeutics GmbH
  • Kadmon Corp LLC
  • Kasiak Research Pvt Ltd
  • Kyorin Pharmaceutical Co Ltd
  • Lung Therapeutics Inc
  • Merck & Co Inc
  • miRagen Therapeutics Inc
  • MorphoSys AG
  • Nuevolution AB
  • Pharmaxis Ltd
  • Promedior Inc
  • ProMetic Life Sciences Inc
  • Pulmatrix Inc
  • Re-Pharm Ltd
  • Redx Pharma Plc
  • Respira Therapeutics Inc
  • Ribomic Inc
  • Saje Pharma LLC
  • Samumed LLC
  • Sanofi
  • Sorrento Therapeutics Inc
  • SPR Biosciences LLC
  • Therabron Therapeutics Inc
  • Unity Biotechnology Inc
  • Vicore Pharma AB
  • Yuhan Corp

薬剤プロファイル

I特発性肺線維症 - 休止中のプロジェクト

I特発性肺線維症 - 開発が中止された製品

I特発性肺線維症 - 製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9294IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2017, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 17, 13, 1, 56 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Idiopathic Pulmonary Fibrosis - Overview
    • Idiopathic Pulmonary Fibrosis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Idiopathic Pulmonary Fibrosis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development
    • AdAlta Ltd
    • Aeolus Pharmaceuticals Inc
    • Allinky Biopharma
    • apceth Biopharma GmbH
    • Apellis Pharmaceuticals Inc
    • Asahi Kasei Pharma Corp
    • aTyr Pharma Inc
    • Biogen Inc
    • Bioneer Corp
    • BLR Bio LLC
    • Bristol-Myers Squibb Company
    • Celgene Corp
    • Celldex Therapeutics Inc
    • Chiesi Farmaceutici SpA
    • Compugen Ltd
    • Cynata Therapeutics Ltd
    • F. Hoffmann-La Roche Ltd
    • FibroGen Inc
    • FibroStatin SL
    • Galapagos NV
    • GenKyoTex SA
    • GlaxoSmithKline Plc
    • Glenmark Pharmaceuticals Ltd
    • Global Blood Therapeutics Inc
    • GNI Group Ltd
    • Histocell SL
    • iBio Inc
    • Inventiva
    • Isarna Therapeutics GmbH
    • Kadmon Corp LLC
    • Kasiak Research Pvt Ltd
    • Kyorin Pharmaceutical Co Ltd
    • Lung Therapeutics Inc
    • Merck & Co Inc
    • miRagen Therapeutics Inc
    • MorphoSys AG
    • Nuevolution AB
    • Pharmaxis Ltd
    • Promedior Inc
    • ProMetic Life Sciences Inc
    • Pulmatrix Inc
    • Re-Pharm Ltd
    • Redx Pharma Plc
    • Respira Therapeutics Inc
    • Ribomic Inc
    • Saje Pharma LLC
    • Samumed LLC
    • Sanofi
    • Sorrento Therapeutics Inc
    • SPR Biosciences LLC
    • Therabron Therapeutics Inc
    • Unity Biotechnology Inc
    • Vicore Pharma AB
    • Yuhan Corp
  • Idiopathic Pulmonary Fibrosis - Drug Profiles
    • AB-22 - Drug Profile
    • acALY-18 - Drug Profile
    • AD-114 - Drug Profile
    • AEOL-10150 - Drug Profile
    • AF-102 - Drug Profile
    • AIK-3b - Drug Profile
    • Antisense RNAi Oligonucleotide for Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis - Drug Profile
    • Antisense RNAi Oligonucleotide to Inhibit HSP47 for Idiopathic Pulmonary Fibrosis - Drug Profile
    • APL-1 - Drug Profile
    • ATYR-1923 - Drug Profile
    • BG-00011 - Drug Profile
    • BLR-500 - Drug Profile
    • BMS-986020 - Drug Profile
    • C-21 - Drug Profile
    • CC-90001 - Drug Profile
    • CDX-0158 - Drug Profile
    • CG-1011 - Drug Profile
    • CGEN-25009 - Drug Profile
    • CM-101 - Drug Profile
    • CT-365 - Drug Profile
    • CWHM-12 - Drug Profile
    • D-9030 - Drug Profile
    • FSMAB-26 - Drug Profile
    • FST-12 - Drug Profile
    • GBT-1118 - Drug Profile
    • GBT-440 - Drug Profile
    • gefapixant - Drug Profile
    • GKT-831 - Drug Profile
    • GLPG-1690 - Drug Profile
    • GLPG-2938 - Drug Profile
    • GRC-388XX - Drug Profile
    • Grx1-iSPERSE - Drug Profile
    • GSK-3008348 - Drug Profile
    • HEC-585 - Drug Profile
    • HR-017 - Drug Profile
    • IBIOCFB-03 - Drug Profile
    • ICG-001 - Drug Profile
    • IGP-002 - Drug Profile
    • ISTH-0047 - Drug Profile
    • IVA-337 - Drug Profile
    • KAR-5585 - Drug Profile
    • KBP-7018 - Drug Profile
    • KD-025 - Drug Profile
    • lebrikizumab - Drug Profile
    • LT-1001 - Drug Profile
    • LTI-03 - Drug Profile
    • MMI-0100 - Drug Profile
    • Monoclonal Antibodies to Inhibit WISP1 for Idiopathic Pulmonary Fibrosis - Drug Profile
    • MOR-107 - Drug Profile
    • MRG-201 - Drug Profile
    • NAS-911 - Drug Profile
    • Neumomir - Drug Profile
    • NUE-7770 - Drug Profile
    • OATD-01 - Drug Profile
    • OLX-101 - Drug Profile
    • OLX-201 - Drug Profile
    • omipalisib - Drug Profile
    • P-013 - Drug Profile
    • pamrevlumab - Drug Profile
    • PBF-1129 - Drug Profile
    • PBI-4050 - Drug Profile
    • pirfenidone - Drug Profile
    • pirfenidone - Drug Profile
    • PRI-724 - Drug Profile
    • PRM-151 - Drug Profile
    • PUR-1500 - Drug Profile
    • PXS-4820 - Drug Profile
    • RBM-005 - Drug Profile
    • RBM-006 - Drug Profile
    • Refacell-IPF - Drug Profile
    • RP-0217 - Drug Profile
    • RT-1840 - Drug Profile
    • RT-234 - Drug Profile
    • SAR-156597 - Drug Profile
    • SM-04646 - Drug Profile
    • Small Molecule to Antagonize AlphaV and Beta6 for Fibrosis - Drug Profile
    • Small Molecules for COPD and IPF - Drug Profile
    • Small Molecules for Idiopathic Pulmonary Fibrosis - Drug Profile
    • Small Molecules for Idiopathic Pulmonary Fibrosis - Drug Profile
    • Small Molecules for Idiopathic Pulmonary Fibrosis - Drug Profile
    • Small Molecules for Liver Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile
    • Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile
    • Small Molecules to Antagonize Integrins for Idiopathic Pulmonary Fibrosis - Drug Profile
    • Small Molecules to Inhibit Autotaxin for Idiopathic Pulmonary Fibrosis and Metastatic Lung Cancer - Drug Profile
    • Small Molecules to Inhibit CHIT-1 for IPF and COPD - Drug Profile
    • Small Molecules to Inhibit LOXL2 for Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Liver Fibrosis and Non-Alcoholic Steatohepatitis - Drug Profile
    • Small Molecules to Inhibit MRTF and SRF for Idiopathic Pulmonary Fibrosis - Drug Profile
    • Small Molecules to Inhibit Porcupine for Immunology, Respiratory, Gastrointestinal and Metabolic Disorders - Drug Profile
    • Small Molecules to Inhibit PTPN13 for Idiopathic Pulmonary Fibrosis - Drug Profile
    • SPL-334 - Drug Profile
    • SPL-334.1 - Drug Profile
    • SPL-891.1 - Drug Profile
    • Stem Cell Therapy for Genito Urinary System And Sex Hormone Diseases, Immunology, Metabolic Disorders, Oncology and Respiratory Disease - Drug Profile
    • Stem Cell Therapy for Idiopathic Lung Fibrosis and Asthma - Drug Profile
    • Stem Cell Therapy for Idiopathic Pulmonary Fibrosis - Drug Profile
    • Stem Cell Therapy for Idiopathic Pulmonary Fibrosis - Drug Profile
    • Synthetic Peptide to Antagonize CD168 for Dermatology, Musculoskeletal, Oncology and Respiratory Disorders - Drug Profile
    • TD-139 - Drug Profile
    • thrombomodulin alfa - Drug Profile
    • tipelukast - Drug Profile
    • vismodegib - Drug Profile
    • Wnt-001 - Drug Profile
    • YH-siRNA1 - Drug Profile
    • ZL-2102 - Drug Profile
  • Idiopathic Pulmonary Fibrosis - Dormant Projects
  • Idiopathic Pulmonary Fibrosis - Discontinued Products
  • Idiopathic Pulmonary Fibrosis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Ltd, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals Inc, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Allinky Biopharma, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by apceth Biopharma GmbH, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Apellis Pharmaceuticals Inc, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Asahi Kasei Pharma Corp, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by aTyr Pharma Inc, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Biogen Inc, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Bioneer Corp, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by BLR Bio LLC, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Celgene Corp, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Celldex Therapeutics Inc, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Chiesi Farmaceutici SpA, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Compugen Ltd, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Cynata Therapeutics Ltd, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by FibroGen Inc, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by FibroStatin SL, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Galapagos NV, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by GenKyoTex SA, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Global Blood Therapeutics Inc, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by GNI Group Ltd, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Histocell SL, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by iBio Inc, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Inventiva, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Kadmon Corp LLC, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Kasiak Research Pvt Ltd, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Lung Therapeutics Inc, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Merck & Co Inc, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by miRagen Therapeutics Inc, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by MorphoSys AG, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Nuevolution AB, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Pharmaxis Ltd, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Promedior Inc, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Pulmatrix Inc, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Re-Pharm Ltd, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Redx Pharma Plc, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Respira Therapeutics Inc, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Ribomic Inc, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Saje Pharma LLC, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Samumed LLC, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Sanofi, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Sorrento Therapeutics Inc, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by SPR Biosciences LLC, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Therabron Therapeutics Inc, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Unity Biotechnology Inc, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Vicore Pharma AB, H1 2017
  • Idiopathic Pulmonary Fibrosis - Pipeline by Yuhan Corp, H1 2017
  • Idiopathic Pulmonary Fibrosis - Dormant Projects, H1 2017
  • Idiopathic Pulmonary Fibrosis - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Idiopathic Pulmonary Fibrosis - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Idiopathic Pulmonary Fibrosis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top